Infant Phototherapy Market Analysis
The Global Infant Phototherapy Device Market will reach US$ 135.97 million by 2032 from US$ 96.44 million in 2023. It is projected to increase at a CAGR of 3.89% from 2024 to 2032.
Phototherapy devices are used to treat infant jaundice, which is frequently perceived in newborn babies. Phototherapy is the most popular method for lowering the level of bilirubin, a compound that causes jaundice. During phototherapy, the infant is exposed to intense fluorescent light while lying in a plastic cot, and its bare skin absorbs the light. This treatment utilizes a specific wavelength of light that breaks bilirubin into a more straightforward water-soluble form, readily excreted through urine and stool.
Request a free sample copy of the report: https://www.renub.com/infant-phototherapy-device-market-p.php
Neonatal jaundice affects millions of newborns worldwide each year, making it one of the most common conditions requiring medical intervention in infants. Phototherapy is the standard treatment for neonatal jaundice. It involves exposing the infant's skin to specific wavelengths of light, which help break down excess bilirubin and facilitate its elimination from the body.
Several factors contribute to the growth of the infant phototherapy device market. Firstly, technological advancements have led to the development of more efficient and user-friendly phototherapy devices. Modern devices use light-emitting diodes (LEDs) or fiber-optic technology to deliver precise and targeted light therapy, reducing treatment duration and minimizing potential side effects.
The increasing emphasis on neonatal care and infant health has also spurred demand for phototherapy devices. Healthcare providers prioritize early detection and treatment of neonatal jaundice to prevent complications such as kernicterus, a severe form of brain damage caused by high levels of bilirubin. Phototherapy devices play a crucial role in managing neonatal jaundice effectively and preventing long-term neurological impairments in infants.
Despite the market's growth prospects, challenges such as cost constraints, regulatory compliance, and limited access to healthcare in rural areas pose barriers to adoption. However, initiatives to increase awareness, improve affordability, and expand access to neonatal care are expected to drive market growth in the coming years.
North America Infant Phototherapy Device Market
North America has boosted the infant phototherapy devices market due to its early adoption and advanced healthcare infrastructure. Neonatal jaundice is becoming more common in North America, partly because of a rise in prenatal births and blood type incompatibilities between mothers and fetuses. According to the Centers for Disease Control and Prevention, about one out of every ten babies born in the United States in 2022 suffered from preterm birth, leading to increased usage of phototherapy devices. As healthcare systems advance, more babies receive care, improving jaundice detection and treatment. Furthermore, the region has established regulations and procedures for treating neonatal jaundice and prioritizes newborn care. North American healthcare providers are well aware of and proficient in phototherapy devices due to their access to the most recent research findings and therapeutic standards.
Global Infant Phototherapy Devices Company Analysis
Some major companies are present in the global infant phototherapy device industry. These are Ningbo David Medical Device Co., Ltd, Koninklijke Philips N.V., General Electric Company, Inspiration Healthcare Group Plc, Drägerwerk AG Co. KGaA, Ibis Medical Equipment and Systems Pvt Ltd., Weyer GmbH and Natus Medical Incorporated.
Global Infant Phototherapy Devices Company News
In November 2023, Drager announced that it is working with technology partners on the development of an intelligent intensive care unit and has received funding from the Innovative Health Initiative.
In September 2022, GenWorks, a Bengaluru-based business, introduced Billicare, a noninvasive (no needles or pins are used to take blood) technology that analyses a baby's bilirubin levels by attaching a clip to their ears.
In November 2021, NeoLight broadened its portfolio of global newborn care businesses by acquiring Phoenix Technology Group, a leader in the ocular screening sector.
In November 2020, Natus Medical Incorporation announced the acquisition of BabybeGmbh for Innovative Newborn Care Technology. In the neonatal intensive care unit (NICU), Babybe provides technology that allows a mother to interact virtually with her infant.
Light Source – Market breakup in 3 viewpoints:
- Fluorescent Lamps
- Light Emitting Diodes
- Quartz Halogen Lamps
- Gas Discharge Tubes
Configuration – Market breakup in 2 viewpoints:
- Mobile Device
- Fixed Device
End User – Market breakup in 2 viewpoints:
- Hospitals
- Neonatal Clinics
Country – Market breakup of 25 Countries:
- North America
1.1 United States
1.2 Canada
- Europe
2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherland
2.8 Turkey
- Asia Pacific
3.1 China
3.2 Japan
3.3 India
3.4 South Korea
3.5 Thailand
3.6 Malaysia
3.7 Indonesia
3.8 Australia
3.9 New Zealand
- Latin America
4.1 Brazil
4.2 Mexico
4.3 Argentina
- Middle East Africa
5.1 Saudi Arabia
5.2 UAE
5.3 South Africa
All the key players have been covered from 4 Viewpoints:
- Overview
- Product Portfolio
- Recent Development
- Revenue Analysis
Key Players Analysis:
- Ningbo David Medical Device Co.
- Ltd, Koninklijke Philips N.V.
- General Electric Company
- Inapiration Healthcare Group Plc
- Drägerwerk AG Co. KGaA
- Ibis Medical Equipment and Systems Pvt Ltd.
- Weyer GmbH
- Natus Medical Incorporated.
Related Reports:
Global Self-Monitoring Blood Glucose Device Market
About the Company:
Renub Research is a Market Research and Information Analysis company with more than 15 years of experience in Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy, organization, operations, technology, mergers acquisitions, etc. Till now we have published more than 9000 syndicated reports and worked on more than 750 custom research projects. Currently, we are supplying data to EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings and perspectives across a wide range of markets.
Contact Us:
Renub Research
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Email: info@renub.com
LinkedIn: https://in.linkedin.com/company/renub-research
Website: https://www.renub.com/
